Drugs / iGlarLixi
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03130426 | Jun 2017 → Jun 2019 | type 2 diabetes mellitus | Population Health Research Institute | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07307235 | Dec 2025 → Jun 2027 expected | type 2 diabetes mellitus | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07274644 | Mar 2025 → Jun 2026 overdue | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06716424 | Jan 2025 → Jun 2026 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04945070 | Jul 2021 → Jan 2023 | type 2 diabetes mellitus | Institute for Clinical and Experimental Medicine | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT04893148 Comparator | May 2020 → Dec 2021 | hyperglycemia, type 2 diabetes mellitus | Chungbuk National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04196231 Comparator | Nov 2019 → Sep 2020 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Sanofi | Results Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin sanofi.com ↗
The study met both primary endpoints with Soliqua demonstrating noninferiority of blood sugar (HbA 1c ) reduction and superiority on body weight change from baseline compared to premixed insulin. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | Sanofi | Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin sanofi.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iGlarLixi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274644 ↗ |
| Known as | Suliqua | “iGlarLixi (Suliqua®) is a once-daily fixed-ratio combination of basal insulin analogue glargine 100 U/ml and a GLP-1 RA lixisenatide.” PMID 38653903 ↗ Apr 2024 |
| Route | Subcutaneous | “Drug: iGlarLixi - sc injection” NCT03130426 ↗ |